Hirsutism affects between 5 to 15 p...

Hirsutism affects between 5 to 15 percent of adult women scrutinizeed for the condition. The excessive product of coarse hair in a male-like pattern can cause significant distress and have multiple negative inferences for patients. Hyperandrogenism usually causes hirsutism. A review by way of Azziz stresses the need for a systematic evaluation of the patient and use of combination therapy.

The first degree in the evaluation of hirsutism is confirmation of excessive coarse (terminal) hairs in a male-like pattern, because many patients who complain of excessive hair growing do not have true hirsutism. Several scoring combination of parts to form a wholes have been developed, but they must be adapted to the ethnic and cultural arrange to which each patient belongs, because material part hair is regarded very differently from different cultures.

The other step involves the identification of the disorders (eg adrenal hyperplasia, diabetes mellitus, thyroid dysfunction, ovulatory conditions) that could contribute to the etiology or complicate the management of hirsutism. The principally common causes of hirsutism are androgenic. Approximately 70 to 80 percent of women with androgen exces have hirsutism. The principally common cause of androgen exces is polycystic ovary syndrome (PCOS) Rarer androgenic causes include the insulin-resistant acanthosis nigricans syndrome any forms of adrenal hyperplasia, and ovarian or adrenal androgen-secreting tumors. Approximately 5 to 15 percent of hirsutism cases are idiopathic (i.e., an underlying cause cannot be identified). a certain number of of these women are believed to have enzyme overactivity in the hair follicles, causing hirsutism in spite of normal circulating hormone levels

Establishing the etiology of hirsutism hangs on a thorough medical and menstrual history plus a physical examination, followed by way of laboratory and other diagnostic criterions targeting the most probable cause for the individual patient. Appropriate proofs may include thyroid function; basal 17-hydroxyprogesterone flat during the follicular phase of menstruation to not include nonclassic adrenal hyperplasia; blood grape-sugar and insulin levels; and measures of circulating androgen of the same heights (total and free testosterone and dehydroepiandrosterone sulfate).

Pharmacologic treatment is directed at the underlying cause of hirsutism, with special attention given to associated risk factors. More than the same half of women with PCO are at significant risk of insulin resistance and diabetes. Suppression of ovarian androgens usually is obtained from one side the use of combined oral contraceptives. Use of estrogen alone (125 mg of conjugated equine estrogen daily) in appropriate women has been commited Oral contraceptives may be combined with long-acting gonadotropin-releasing hormone (Gn-RH) analogs, so as Lupron Depot in a dosage of 375 mg for month, but this approach generally requires brace to three cycles for weight Insulin resistance may respond to weight los or therapy with metformin or troglitazone, however the effect on hirsutism may be virtuous The most effective treatments combine androgen suppression with peripheral androgen blockade. Androgen-receptor blocker include spironolactone, flutamide, finasteride, and cyproterone acetate. These remedys have teratogenic potential and require stable contraception.

In addition to medical treatments, most numerous women with hirsutism seek local treatments to minimize the appearance of unwanted hair. Shaving does not increase hair produce Depilating agents can cause chronic skin irritation. Mechanical hair removal by the agency of waxing or plucking is discouraged because of the risk of trauma, ingrown hairs, and folliculitis. Electrolysis and laser therapy can be auspicious but have unwanted side weights such as blistering and pigmentation changes. Eflornithine hydrochloride 139 percent cream is approved by means of the U.S. Food and physic Administration for treatment of unwanted facial hair. This agent deads and miniaturizes hair growth yet appears to require continuous application. It has been associated with improvement in 60 percent of cases in initial studies and requires at least eight weeks of treatment for effectiveness.

Azziz R The evaluation and management of hirsutism. Obstet Gynecol May 2003;101:995-1007

COPYRIGHT 2004 American Academy of Family Physicians

COPYRIGHT 2004 Gale Group